Corbus Pharmaceuticals Holdings Stock News

Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of -7.39% also noticed, India Ault Global Holdings, Inc. (AMEX:DPW) encountered a rapid change of 0.00% in the last hour of Fridays The post Remarkable Stock Buzz: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Ault Global Holdings, Inc. (AMEX:DPW) appeared first on Stocks Equity .

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Analysts at Jefferies Financial Group dropped their FY2025 EPS estimates for Corbus Pharmaceuticals in a report issued on Tuesday, November 30th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings per share of $0.92 for the year, down from their prior estimate of []

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Analysts at Jefferies Financial Group raised their FY2021 EPS estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, November 30th. Jefferies Financial Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings of ($0.41) per share for the year, up from their previous forecast []

Corbus Pharmaceuticals (NASDAQ:CRBP)s stock had its hold rating reiterated by Royal Bank of Canada in a research note issued to investors on Tuesday, Analyst Price Targets reports. They currently have a $2.00 price target on the biopharmaceutical companys stock. Royal Bank of Canadas price objective would suggest a potential upside of 119.32% from the stocks []

In the last trading session, 1.11 million shares of the Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) were traded, and its beta was 1.78. Most recently the companys share price was $0.88, and it changed around $0.0 or -0.53% from the last close, which brings the market valuation of the company to $108.75M. CRBP currently trades at Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP): Stock Forecast For 2021 Sees A A Decline Of -27.89% Read More »

Walleye Trading LLC purchased a new stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 56,659 shares of the biopharmaceutical companys stock, valued at approximately $104,000. Several other institutional investors and hedge funds have also recently made changes []

Zacks Investment Research upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. The brokerage currently has $1.25 price target on the biopharmaceutical companys stock. According to Zacks, Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company []

Vanguard Group Inc. lifted its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 43.6% during the second quarter, Holdings Channel reports. The fund owned 5,462,050 shares of the biopharmaceutical companys stock after buying an additional 1,658,273 shares during the quarter. Vanguard Group Inc.s holdings in Corbus Pharmaceuticals were worth $9,996,000 as of its []

10 penny stocks to watch this week. The post 10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D.

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.1